Emerging evidence from recent studies suggests that CBX proteins are associated with a variety of tumors. CBX2 inhibition induces cancer cell death, positioning CBX2 as an attractive drug target for the treatment of advanced prostate cancer [8]. This evidence concerns the gene CBX1 and cancer.